Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin. [electronic resource]
Producer: 20170110Description: 275-286 p. digitalISSN:- 1873-4995
- Animals
- Antibiotics, Antineoplastic -- administration & dosage
- Antibodies, Monoclonal -- administration & dosage
- Carcinoma -- drug therapy
- Cell Line, Tumor
- Colonic Neoplasms -- drug therapy
- Dose-Response Relationship, Drug
- Doxorubicin -- administration & dosage
- Drug Compounding
- Female
- Hyaluronan Receptors -- immunology
- Immunoconjugates -- administration & dosage
- Mice
- Mice, Inbred BALB C
- NIH 3T3 Cells
- Neoplastic Stem Cells -- drug effects
- Polyethylene Glycols -- administration & dosage
- Tissue Distribution
- Tumor Burden -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.